Research & development decreased 37.6%
Research & development changed -37.6% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -37.6% from the comparable as-filed period.
Cash & equivalents changed +35.1% from the comparable as-filed period.
Stock-based compensation changed +79.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed -12.0% from the comparable as-filed period.
Current assets changed +39.2% from the comparable as-filed period.
Total assets changed +35.0% from the comparable as-filed period.
Net income changed -12.0% from the comparable as-filed period.
Stockholders' equity changed +8.6% from the comparable as-filed period.
Cash & equivalents changed -19.2% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.